Silence Therapeutics (LON:SLN) Stock Price Down 0.9% – Should You Sell?

Silence Therapeutics plc (LON:SLN) shares were down 0.9% during trading on Thursday . The stock traded as low as GBX 512 ($6.46) and last traded at GBX 535 ($6.75). Approximately 913,528 shares were traded during mid-day trading, an increase of 1,040% from the average daily volume of 80,100 shares. The stock had previously closed at GBX 540 ($6.82).

Silence Therapeutics Stock Performance

The firm’s fifty day moving average is GBX 535 and its 200 day moving average is GBX 535. The company has a market cap of £480.35 million and a PE ratio of -11.01. The company has a current ratio of 4.52, a quick ratio of 4.36 and a debt-to-equity ratio of 0.80.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.